Halozyme Therapeutics, Inc. (NASDAQ:HALO) went up by 2.37% from its latest closing price compared to the recent 1-year high of $29.77. The company’s stock price has collected -0.04% of loss in the last five trading sessions. Press Release reported on 09/10/20 that Halozyme Announces Janssen Submission For FDA Approval Of DARZALEX FASPRO(TM) (daratumumab and hyaluronidase-fihj) For The Treatment Of Patients With Light Chain (AL) Amyloidosis
Is It Worth Investing in Halozyme Therapeutics, Inc. (NASDAQ :HALO) Right Now?
Halozyme Therapeutics, Inc. (NASDAQ:HALO) scored a price-to-earnings ratio above its average ratio, recording 149.60 x from its present earnings ratio. Plus, the 36-month beta value for HALO is at 1.60. Opinions of the stock are interesting as 9 analysts out of 11 who provided ratings for Halozyme Therapeutics, Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $32.73, which is $5.51 above the current price. HALO currently public float of 131.63M and currently shorts hold a 11.72% ratio of that float. Today, the average trading volume of HALO was 1.10M shares.
HALO’s Market Performance
HALO stocks went down by -0.04% for the week, with a monthly drop of -6.55% and a quarterly performance of 19.61%, while its annual performance rate touched 70.09%. The volatility ratio for the week stands at 3.56% while the volatility levels for the past 30 days are set at 3.13% for Halozyme Therapeutics, Inc.. The simple moving average for the period of the last 20 days is -1.27% for HALO stocks with a simple moving average of 23.57% for the last 200 days.
Analysts’ Opinion of HALO
Many brokerage firms have already submitted their reports for HALO stocks, with JP Morgan repeating the rating for HALO by listing it as a “Overweight.” The predicted price for HALO in the upcoming period, according to JP Morgan is $28 based on the research report published on September 14th of the current year 2020.
The Benchmark Company, on the other hand, stated in their research note that they expect to see HALO reach a price target of $39. The rating they have provided for HALO stocks is “Buy” according to the report published on July 1st, 2020.
Piper Sandler gave a rating of “ Overweight” to HALO, setting the target price at $27 in the report published on February 5th of the current year.
HALO Trading at -1.55% from the 50-Day Moving Average
After a stumble in the market that brought HALO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.99% of loss for the given period.
Volatility was left at 3.13%, however, over the last 30 days, the volatility rate increased by 3.56%, as shares sank -0.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.88% lower at present.
During the last 5 trading sessions, HALO fell by -0.04%, which changed the moving average for the period of 200-days by +41.78% in comparison to the 20-day moving average, which settled at $28.04. In addition, Halozyme Therapeutics, Inc. saw 56.18% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at HALO starting from MATSUI CONNIE, who sold 32,000 shares at the price of $27.06 back on Sep 11. After this action, MATSUI CONNIE now owns 216,753 shares of Halozyme Therapeutics, Inc., valued at $865,792 using the latest closing price.
LaBarre Michael J., the SVP, Chief Technical Officer of Halozyme Therapeutics, Inc., sold 12,000 shares at $28.30 during a trade that took place back on Aug 20, which means that LaBarre Michael J. is holding 170,800 shares at $339,564 based on the most recent closing price.
Stock Fundamentals for HALO
Current profitability levels for the company are sitting at:
- -18.70 for the present operating margin
- +76.76 for the gross margin
The net margin for Halozyme Therapeutics, Inc. stands at -36.86. The total capital return value is set at -8.43, while invested capital returns managed to touch -19.05. Equity return is now at value -31.70, with -8.10 for asset returns.
Based on Halozyme Therapeutics, Inc. (HALO), the company’s capital structure generated 438.72 points at debt to equity in total, while total debt to capital is 81.44. Total debt to assets is 71.14, with long-term debt to equity ratio resting at -3.15. Finally, the long-term debt to capital ratio is 417.42.
When we switch over and look at the enterprise to sales, we see a ratio of 12.96, with the company’s debt to enterprise value settled at 0.16. The receivables turnover for the company is 4.38 and the total asset turnover is 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.35.